Bacterial pneumonia may trigger the development of acute lung injury (ALI) and/or acute respiratory distress (ARDS). Some of the key pathological features of ALI/ARDS include an acute inflammatory response in the alveoli and endothelial injury. Complications of these conditions are pulmonary hypo/hypertension and myocardial depression. The murine acute lung injury model is able to mimic the cascade of inflammatory responses common to ALI/ARDS in humans and is a platform for testing the efficacy of novel compounds that may aid in protecting against the development of this condition.
Preclinical Drug Efficacy Studies
Animals are anesthetized, orally intubated with a sterile plastic catheter and challenged with an intratracheal instillation of LPS. At study completion lungs are lavaged with 3 ml of saline. Lavage fluid is collected for downstream measures. The administration of compounds is performed according to the schedule set-forth in the study protocol.
Kitamura Y, Hashimoto S, Mizuta N, Kobayashi A, Kooguchi K, Fujiwara I, Nakajima H. (2001) Fas/FasL-dependent Apoptosis of Alveolar Cells after Lipopolysaccharide-induced Lung Injury in Mice. American Journal of Respiratory and Critical Care Medicine; 163: 762-9.
Kristof AS, Goldberg P, Laubach V, Hussain SNA. (1998) Role of Inducible Nitric Oxide Synthase in Endotoxin-Induced Acute Lung Injury. American Journal of Respiratory and Critical Care Medicine; 158: 1883-89.
Martin TR, Mathison JC, Tobias PS, Leturcq DJ, Moriarty AM, Maunder RJ, Ulevitch RJ. (1992) Effects of Lipopolysaccharide Binding Protein on Alveolar Macrophages. The Journal of Clinical Investigation; 90: 2209-19.